AccessibilityHelpAbout Us
Santen Pharmaceutical logo

Santen Pharmaceutical(OTC) SNPHY

Market Cap$3.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+35%
5 Year-18%
1 Year-4%
1 Month-9%
$11.05
+2.79%
+0.30Today
Santen Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 10.752026-09-24
Santen Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.03%USD 11.442026-09-17
1 month-8.7%USD 11.782026-08-25
3 month-15.77%USD 12.762026-06-26
Year to date+5.51%USD 10.192025-12-31
1 year-3.69%USD 11.162025-09-24
3 year+20.79%USD 8.902023-09-25
5 year-18.42%USD 13.182021-09-24
Since inception+34.69%USD 7.982011-08-31

Santen Pharmaceutical Financials at a Glance

Market Cap

$3.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥296.76B

Net Income (TTM)

¥39.34B

EPS (TTM)

$0.77

P/E Ratio

13.91

Dividend

$0.24

Beta (Volatility)

0.27 (Low)

Price

$11.05

Volume

2,163

Open

$11.00

Previous Close

$11.05

Daily Range

$11.00 - $11.05

52-Week Range

$9.22 - $13.93

Estimated Earnings Date

May 11, 2026

SNPHY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. is a global enterprise focused on the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, particularly in ophthalmology. With a strong pipeline of products, Santen aims to address various eye conditions, including glaucoma and ocular hypertension.

Products and Services
  • Innovative treatments for glaucoma and ocular hypertension
  • Over-the-counter pharmaceutical products for eye care
  • Research and development in myopia and other eye ailments
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical trials
  • Expansion into European and Asian markets for new therapies
  • Focus on addressing unmet needs in ophthalmic conditions
Financial Highlights
  • Recent quarterly revenue of 69.87 billion JPY, showing resilience
  • Trailing twelve months (TTM) net income of 72.89 billion JPY
  • TTM return on equity at 13.39%, indicating effective capital use
Santen Pharmaceutical Co., Ltd. has established itself as a leader in the ophthalmic pharmaceutical sector, with a commitment to innovation and patient care. The company's diverse product offerings and robust pipeline position it well for future growth, particularly in addressing significant unmet medical needs in eye health. Recent financial performance reflects stability and potential for continued success, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Sep 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3,968

CEO

Takeshi Ito

Website

www.santen.co.jp

Headquarters

Kita, OS 530-8552, JP

SNPHY Financials

Key Financial Metrics (TTM)

Gross Margin

56.10%

Operating Margin

15.67%

Net Income Margin

13.25%

Return on Equity

13.39%

Return on Capital

14.39%

Return on Assets

9.30%

Earnings Yield

7.19%

Dividend Yield

2.22%

Payout Ratio

31.76%

Stock Overview

Market Cap

$3.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

321.21M

Volume

2.16K

Avg. Volume

2.82K

Financials (TTM)

Gross Profit

¥166.48B

Operating Income

¥46.53B

EBITDA

¥66.18B

Operating Cash Flow

¥42.19B

Capital Expenditure

-¥6.01B

Free Cash Flow

¥36.17B

Cash & ST Invst.

¥77.74B

Total Debt

¥30.80B

Santen Pharmaceutical Performance Analysis

Santen Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 2,059,878,301-13.1%
20242024-03-31JPY 2,090,975,9881.5%
20252025-03-31JPY 1,967,879,818-5.9%
20262026-03-31JPY 1,935,231,038-1.7%
Santen Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-302.3%
Q32025-12-315.5%
Q42026-03-3111.0%
Q12026-06-30-15.2%
Santen Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY -0.29N/A
20242024-03-31JPY 0.50N/A
20252025-03-31JPY 0.6835.7%
20262026-03-31JPY 0.7611.0%
Santen Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3038.9%
Q32025-12-313.3%
Q42026-03-3193.4%
Q12026-06-30-52.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥69.87B

+1.6%

Gross Profit

¥38.19B

+2.9%

Gross Margin

54.66%

N/A

Market Cap

$3.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$870.22K

N/A

Employees

3,968

N/A

Net Income

¥7.29B

+24.0%

EBITDA

¥12.95B

+7.3%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥77.74B

-8.1%

Total Debt

¥30.80B

+12539.9%

Accounts Receivable

¥63.19B

-6.2%

Inventory

¥64.64B

+9.1%

Long Term Debt

¥30.80B

N/A

Short Term Debt

¥0.00

N/A

Return on Assets

9.30%

N/A

Return on Invested Capital

13.54%

N/A

Free Cash Flow

¥4.36B

+10649.8%

Operating Cash Flow

¥5.33B

+9870.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAHLYMediPal Holdings Corporation
$19.81+5.60%
BVNKFBavarian Nordic A/S
$32.57+0.00%
HAWPFHaw Par Corporation Limited
$10.80+0.00%
SHWGYShandong Weigao Group Medical Polymer Company Limited
$1.64+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About SNPHY

What is the current price of Santen Pharmaceutical?

Santen Pharmaceutical is trading at $11.05 per share.

What is the 52-week range for Santen Pharmaceutical?

Over the past 52 weeks, Santen Pharmaceutical has traded between $9.22 and $13.93.

How much debt does Santen Pharmaceutical have?

As of the most recent reporting period, Santen Pharmaceutical reported total debt of ¥190.78M.

How much cash does Santen Pharmaceutical have on hand?

Santen Pharmaceutical reported ¥481.51M in cash and cash equivalents in its most recent financial results.

What is Santen Pharmaceutical’s dividend yield?

Santen Pharmaceutical currently has a dividend yield of 2.22%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services